Inclusion Criteria:

- Histologically confirmed hepatic colorectal metastasis by percutaneous hepatic biopsy

- Imaging evidence of liver metastasis by CT helical scan

- Resectable disease, as determined by a surgeon with hepatic surgery expertise (at
least 10 resections performed per year)

- Resectable, defined as a sparing of 2 adjacent liver segments with adequate
vascular inflow and outflow and hepatic remnant volume

- Minor resections (less than a hemihepatectomy) or major resections
(hemihepatectomy or extended hepatectomy) allowed

- Bilobar resection allowed, including atypical resections

- No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen,
and pelvis

- Performance status - Zubrod 0-1

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 9.0 g/dL

- Bilirubin no greater than 2 mg/dL

- AST and ALT no greater than 300 IU/L

- No preexisting chronic hepatic disease (e.g., chronic active hepatitis or cirrhosis)
that would preclude surgical resection of metastases

- Creatinine no greater than 1.5 mg/dL

- Creatinine clearance 60 mL/min

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other malignancy within the past 5 years except completely resected nonmelanoma
skin cancer or carcinoma in situ of the cervix

- No preexisting grade 2 or greater peripheral neuropathy

- No concurrent uncontrolled illness

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study compliance

- No concurrent biologic therapy

- No concurrent sargramostim (GM-CSF)

- More than 6 months since prior adjuvant fluorouracil-based chemotherapy

- No prior chemotherapy for liver metastasis

- No prior oxaliplatin for colorectal cancer

- No prior or concurrent hepatic artery infusion chemotherapy for metastatic disease

- No prior or concurrent radiotherapy for metastatic disease

- No prior or concurrent radiofrequency ablation for metastatic disease

- No prior or concurrent cryotherapy/other ablative techniques for metastatic disease

- No other concurrent investigational therapy

- No concurrent oral anticoagulation